Related Experiment Video
Updated: Aug 29, 2025
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy
Sheng Zhang1, Ganesh Rao2, Amy Heimberger3
1Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Brain tumors are among the 10 leading causes of cancer-related death and present unique treatment challenges due to their critical location, genetic heterogeneity, and the blood-brain barrier. Recent advances in targeted immunotherapy and immune checkpoint blocking therapy provide alternative therapeutic strategies for brain tumors. Fibrinogen-like protein 2 (FGL2), which induces transformation from low-grade glioma to high-grade glioblastoma, is a type II membrane protein that is highly expressed in both host immune cells and tumor cells. Studies have uncovered multiple forms of FGL2 proteins with a broad range of roles in inducing immune tolerance and avoiding immune surveillance in tumor cells. Of note, presence of FGL2 transforms low grade to high grade brain tumors via promoting Treg, macrophages, and perhaps stemness. Absence (knockout) of FGL2 in tumor cells (not in host cells) induces CD103 DC cells, which triggers tumor specific CD8 +T cell activity to reject brain tumor progression. Immunotherapies targeting FGL2 have shown great promise in improving survival time in murine models. In this article, we will summarize the biological function of FGL2 in immune and tumor cells.
Insights
Fibrinogen-like protein 2 (FGL2) promotes brain tumor growth and immune evasion. Targeting FGL2 in tumor cells can enhance anti-tumor immunity and potentially treat brain tumors.
Area of Science:
- Neuro-oncology
- Immunology
- Molecular Biology
Background:
- Brain tumors are a leading cause of cancer death, posing treatment challenges.
- Targeted immunotherapy offers new therapeutic avenues for brain tumors.
- Fibrinogen-like protein 2 (FGL2) is implicated in brain tumor progression and immune suppression.
Purpose of the Study:
- To summarize the biological functions of FGL2 in immune and tumor cells.
- To explore FGL2's role in the transformation of low-grade to high-grade brain tumors.
- To highlight FGL2-targeted immunotherapies for brain tumors.
Main Methods:
- Review of existing literature on FGL2 function in brain tumors.
- Analysis of FGL2's impact on immune cells like Tregs and macrophages.
- Investigation of FGL2's role in promoting tumor stemness and immune evasion.
Main Results:
- FGL2 expression in tumor cells promotes immune tolerance and transformation to high-grade tumors.
- Absence of FGL2 in tumor cells enhances anti-tumor CD8+ T cell responses.
- FGL2 knockout in tumor cells induces CD103+ dendritic cells, activating tumor-specific immunity.
Conclusions:
- FGL2 is a key factor in brain tumor immune evasion and progression.
- Targeting FGL2 presents a promising strategy for brain tumor immunotherapy.
- Modulating FGL2 can potentially reverse immune suppression and enhance tumor rejection.
Related Concept Videos
00:49The Blood-brain Barrier
02:38Mitogens and the Cell Cycle